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Abstract
Beneficial effects of green tea polyphenols (GTP) against obesity have been reported, however, the mechanism of this
protection is not clear. Therefore, the objective of this study was to identify GTP-targeted genes in obesity using the high-
fat-diet-induced obese rat model. A total of three groups (n=12/group) of Sprague Dawley (SD) female rats were tested,
including the control group (rats fed with low-fat diet), the HF group (rats fed with high-fat diet), and the HF+GTP group
(rats fed with high-fat diet and GTP in drinking water). The HF group increased body weight as compared to the control
group. Supplementation of GTP in the drinking water in the HF+GTP group reduced body weight as compared to the HF
group. RNA from liver samples was extracted for gene expression analysis. A total of eighty-four genes related to obesity
were analyzed using PCR array. Compared to the rats in the control group, the rats in the HF group had the expression
levels of 12 genes with significant changes, including 3 orexigenic genes (Agrp, Ghrl, and Nr3c1); 7 anorectic genes (Apoa4,
Cntf, Ghr, IL-1b, Ins1, Lepr, and Sort); and 2 genes that relate to energy expenditure (Adcyap1r1 and Adrb1). Intriguingly, the
HF+GTP group restored the expression levels of these genes in the high-fat-induced obese rats. The protein expression
levels of IL-1b and IL-6 in the serum samples from the control, HF, and HF+GTP groups confirmed the results of gene
expression. Furthermore, the protein expression levels of superoxide dismutase-1 (SOD1) and catechol-O-methyltransferase
(COMT) also showed GTP-regulated protective changes in this obese rat model. Collectively, this study revealed the
beneficial effects of GTP on body weight via regulating obesity-related genes, anti-inflammation, anti-oxidant capacity, and
estrogen-related actions in high-fat-induced obese rats.
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Introduction
Over two-thirds of the adults in the United States are
overweight or obese and over one-third of U.S. adults are obese
[1]. The prevalence of obesity is rising rapidly in many countries,
so obesity is seen as a global pandemic. The consequences of this
are not only the social and psychological effects of excessive
weight, but also the significant morbidity and premature mortality
associated with the serious medical conditions that obesity
predisposes to, including type II diabetes, hypertension, coronary
artery disease, and various forms of cancer [2,3].
Many risk factors, such as increased caloric intake, reduced
energy expenditure, energy balance influenced by the central
nervous system, adaptive thermogenesis, neuropeptides, and
neurotransmitters, have been recognized to contribute to obesity
[4]. The role of the interactions between environmental and
genetic factors in the contribution to complex polygenic obesity
and common obesity has been more important as no efficient
treatment, apart from major surgery, currently exists [5].
Therefore, by the discovery of novel genes or new etiological
pathways, innovative therapies, preventive measures, and phar-
macogenetical strategies can be found and/or used in obesity
studies.
Green tea is one of the most popular beverages in the world.
The impacts of green tea consumption on weight loss have been
reported in clinical [6,7,8,9,10,11,12] and laboratory animal
studies [13]. Such an anti-obesity effect of green tea is probably
due to its capacity in elevating thermogenesis and fat oxidation,
lowering lipid peroxidation [14,15], as well as suppressing appetite
and nutrient absorption [16]. Our previous studies suggest the
positive impacts of green tea polyphenols (GTP, extracts of green
tea) could be from its ability in suppressing chronic inflammation
and oxidative stress damage, increasing antioxidant capacities, or
estrogen-related effect [17,18,19,20,21]. However, the effects of
GTP on obesity along with its related mechanism(s) are not clear.
We hypothesize that supplementation of GTP reduces body
weight by regulating obesity related genes; and such changes are
from down-regulating orexigenic genes, stimulating anorectic
genes, increasing energy expenditure, suppressing proinflamma-
tory cytokine production, and/or elevating antioxidant capacity.
Therefore, the present study was designed to not only establish a
reliable high-fat-induced rat model but investigate the potential
benefits of GTP on body weight in these obese rats. Furthermore,
the molecular mechanisms including GTP-targeted genes in
regulating obesity, anti-inflammatory, anti-oxidant capacities,
and estrogen-associated effects were also evaluated to advance
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38332the understanding of beneficial effects of GTP on overweight and/
or obesity.
Materials and Methods
Animals and GTP Treatments
Virgin Sprague Dawley (SD) female rats (n=36, 3-month old,
Harlan Laboratories, Indianapolis, IN, USA) were housed in an
environmentally controlled animal care facility and acclimated for
5 days on an AIN-93M diet and distilled water ad libitum prior to
the start of experiments. The diets were based on a modification of
the AIN-93M diet and supplied by Research Diets Inc. (New
Brunswick, NJ, USA). The same amount of minerals and vitamins
were given to all animals.
Rats were randomized by weight into two groups: 1) control (a
low-fat diet, 10% energy as fat, n=12); or 2) a high-fat diet (HF,
45% energy as fat, n=24) for 4 months. Animals in the control
group continued on a low-fat diet for an additional 4 months (the
control group). Animals in the HF diet group were randomly
divided into two treatments, with (the HF+GTP group, n=12) or
without GTP (the HF group, n=12) in drinking water, in addition
to an HF diet for another 4 months. Daily food consumption was
recorded. Weekly body weight was also recorded. Rats in the
HF+GTP group had free access to distilled water containing 0.5%
(wt/vol) GTP. GTP was purchased from the same source as that
used in our previous studies (Shili Natural Product Company, Inc.,
Guangxi, China) with purity higher than 98.5% [17,18,19,20,21].
Every 1000 mg GTP contained 464 mg (-)-epigallocatechin
gallate, 112 mg (-)-epicatechin gallate, 100 mg (-)-epicatechin,
78 mg (-)-epigallocatechin, 96 mg (-)-gallocatechin gallate, and
44 mg catechin according to high-performance liquid chromatog-
raphy analysis. In our previous study, we provided the same
concentration of GTP (0.5%, wt/vol) in the drinking water to
female rats for 20 weeks and found these was no liver damage to
the studied animals as assessed by liver enzyme activity in serum
[22]. Rats were kept in individual stainless steel cages under a
controlled temperature of 2162uC with a 12 h light-dark cycle.
All procedures were approved by the Texas Tech University
Health Sciences Center Institutional Animal Care and Use
Committee.
Isolation of Total RNA
Rats (11 months old) were anesthetized and euthanized (not
fasted), and liver samples were collected at end of the experiment.
Total RNA was isolated from liver samples from the control, HF,
and HF+GTP groups using an RNeasyH plus mini kit (Qiagen,
Valencia, CA) following the manufacturer’s protocol as described
in our previous study [23]. Briefly, the lysate liver sample was
homogenized, genomic DNA removed, and purified. The RNA
was eluted by 30 mL RNase-free water and stored at 280uC until
use. The total extracted RNA was determined by measuring OD
at 260 nm using a Nano-Drop 1000 Spectrophotometer (Thermo
Scientific, Waltham, MA). The quality and purity of total RNA
were evaluated by agarose gel electrophoresis using Horizon 11.14
(Life Technologies, Gaithersburg, MD). Total RNA samples used
for RT–PCR experiments had good integrity and had OD A260/
A280 ratios between 1.99–2.08 and concentration $45 mg/mL.
The total RNA samples were further treated by DNA-free
TM
DNase (Applied Biosystems, Austin, TX) to remove possible DNA
contamination. Three replicates, each of which were pooled
sample from 3 individual rats in each group (9 rats total), were
analyzed for each of the control, HF, and HF+GTP groups.
Reverse Transcription-PCR
cDNA was prepared using an RT
2 PCR array first strand kit
(SABiosciences Corporation, Frederick, MD) according to man-
ufacturer’s instructions. Briefly, 1 mg of total RNA was mixed with
2 mLo f5 6 gDNA elimination buffer to form a total volume of
10 mL genomic DNA elimination mixture with RNase-free H2O,
incubated at 42uC for 5 min, and chilled on ice immediately. The
mixture was then incubated with a 10 mL RT Cocktail at 42uC for
15 min, and the reaction stopped by heating at 95uC for 5 min to
inactivate the reverse transcriptase. The 20 mL cDNA synthesis
reaction mixture was diluted to 111 mL by adding 91 mL RNase-
free H2O and kept on ice for further use.
Array-based SYBRH Green RT-PCR
Constitutive gene expression profiling was performed using the
RT
2 Profiler
TM PCR array (SABiosciences) related to obesity
signal transduction based on manufacturer’s instructions. The rat
genomic DNA was used first to test the array for quality control.
The gene array profiled the expression of 84 genes including
orexigenic genes, anorectic genes, and genes related to energy
expenditure (Table 1 and Figure 1A, PARN-017A-12, RT
2
Profiler
TM PCR Array Rat Obesity). In addition, the array
included the controls for human genomic DNA contamination,
reverse transcription, positive PCR control, and 5 housekeeping
genes [ribosomal protein large P1 (Rplp1), hypoxanthine phos-
phoribosyltransferase 1 (Hprt1), ribosomal protein L13A (Rpl13a),
lactate dehydrogenase A (Ldha), and actin beta (Actb) (Tables S1,
S2, and S3). These 5 housekeeping genes were used in normalizing
the relative gene expression for data analysis. Briefly, an aliquot of
102 mL diluted cDNA synthesis reaction was mixed with an
experimental cocktail containing 1,275 mL2 6 RT
2 SYBRH
green/fluorescein qPCR master mix (SABiosciences) and
1,173 mL Mili-Q water (18.3 M, pH 6.8) to form the PCR master
mixture. An aliquot of 25 mL of the mixture (a total of 9.0 ng
cDNA) was added to each well of the 96-well PCR array. Real-
time PCR was performed using a two-step cycling program on an
ABI PRISM 7000 System (Applied Biosystems) under the
following conditions: 10 min at 95uC (cycle 1) followed by 40
cycles of 15 s at 95uC and 1 min at 60uC. SYBRH green
fluorescence was detected and recorded. The threshold cycle (CT)
above the background for each reaction was calculated. The
quality control using rat genomic DNA demonstrated all the
targets on this PCR array were detectable as expected and ready
for use (Figure 1B).
IL-1b and IL-6 Analysis
Serum samples were collected from rats (11 months old) at end
of the experiment. Serum proinflammatory cytokines IL-1b and
IL-6 were analyzed by Bio-Plex
TM Rat Cytokine Panel (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) with Luminex 100
Analyzer (Luminex Corporation, Austin, TX) following the
manufacturer’s instruction.
Western Blot
The individual rat liver tissue in the control, HF, and HF+GTP
groups (n=9/group, the same samples analyzed in PCR array)
was resuspended in a Radio Immuno Preciptation Assay (RIPA)
lysis buffer. The samples were homogenized by sonication on ice
with a sonic dismembrator (model 100, Fisher, Pittsburgh, PA).
Similar to the pooling strategy used in PCR array analysis, three
pooled samples were obtained in each of the control, HF, and
HF+GTP groups in which an aliquot of 300 mg protein from 3
individual samples in each group was added together to form a
GTP’s Effects on Obesity
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Position Symbol Description Gene Name
A01 Adcyap1 Adenylate cyclase activating polypeptide 1 Pacap
A02 Adcyap1r1 Adenylate cyclase activating polypeptide 1 receptor 1 PACAP-R1A, PACAPR1, PACAPR1A
A03 Adipoq Adiponectin, C1Q and collagen domain containing Acdc, Acrp30
A04 Adipor1 Adiponectin receptor 1 –
A05 Adipor2 Adiponectin receptor 2 –
A06 Adra2b Adrenergic, alpha-2B-, receptor –
A07 Adrb1 Adrenergic, beta-1-, receptor B1AR, RATB1AR
A08 Agrp Agouti related protein homolog (mouse) –
A09 Apoa4 Apolipoprotein A-IV Apo-AIV, ApoA-IV, apoAIV
A10 Atrn Attractin –
A11 Bdnf Brain-derived neurotrophic factor MGC105254
A12 Brs3 Bombesin-like receptor 3 –
B01 C3 Complement component 3 –
B02 Calca Calcitonin-related polypeptide alpha CAL6, CGRP, Cal1, Calc, RATCAL6, calcitonin
B03 Calcr Calcitonin receptor –
B04 Cartpt CART prepropeptide Cart
B05 Cck Cholecystokinin –
B06 Cckar Cholecystokinin A receptor Cck-ar
B07 Clps Colipase, pancreatic COLQ
B08 Cnr1 Cannabinoid receptor 1 (brain) SKR6R
B09 Cntf Ciliary neurotrophic factor –
B10 Cntfr Ciliary neurotrophic factor receptor –
B11 Crh Corticotropin releasing hormone CRF
B12 Crhr1 Corticotropin releasing hormone receptor 1 –
C01 Drd1a Dopamine receptor D1A D1a, Drd-1, Drd1
C02 Drd2 Dopamine receptor D2 –
C03 Gal Galanin prepropeptide Galn
C04 Galr1 Galanin receptor 1 Galnr1
C05 Gcg Glucagon GLP-1
C06 Gcgr Glucagon receptor MGC93090
C07 Gh1 Growth hormone 1 Gh, RNGHGP
C08 Ghr Growth hormone receptor GHR, BP, MGC124963, MGC156665
C09 Ghrl Ghrelin/obestatin prepropeptide –
C10 Ghsr Growth hormone secretagogue receptor –
C11 Glp1r Glucagon-like peptide 1 receptor Glip, RATGL1RCP
C12 Prlhr Prolactin releasing hormone receptor Gpr10, Uhr-1
D01 Mchr1 Melanin-concentrating hormone receptor 1 Gpr24, Mch-1r, Slc1
D02 Grp Gastrin releasing peptide –
D03 Grpr Gastrin releasing peptide receptor –
D04 HcRt Hypocretin orexin-A
D05 Hcrtr1 Hypocretin (orexin) receptor 1 Hctr1
D06 Hrh1 Histamine receptor H 1 Hisr
D07 Htr2c 5-hydroxytryptamine (serotonin) receptor 2C 5-HT2C, 5-HTR2C, 5HT-1C
D08 Iapp Islet amyloid polypeptide –
D09 IL-1a Interleukin 1 alpha IL-1 alpha
D10 IL-1b Interleukin 1 beta –
D11 IL-1r1 Interleukin 1 receptor, type I –
D12 IL-6 Interleukin 6 ILg6, Ifnb2
E01 IL-6ra Interleukin 6 receptor IL6R1, Il6ra, Il6r
GTP’s Effects on Obesity
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Position Symbol Description Gene Name
E02 Ins1 Insulin 1 –
E03 Ins2 Insulin 2 –
E04 Insr Insulin receptor –
E05 Lep Leptin OB, obese
E06 Lepr Leptin receptor Fa
E07 Mc3r Melanocortin 3 receptor –
E08 Nmb Neuromedin B RGD1562710
E09 Nmbr Neuromedin B receptor NMB-R
E10 Nmu Neuromedin U –
E11 Nmur1 Neuromedin U receptor 1 Gpr66
E12 Npy Neuropeptide Y NPY02, RATNPY, RATNPY02
F01 Npy1r Neuropeptide Y receptor Y1 MGC109393, NPY-1
F02 Nr3c1 Nuclear receptor subfamily 3, group C, member 1 GR, Gcr, Grl
F03 Ntrk1 Neurotrophic tyrosine kinase, receptor, type 1 Trk
F04 Nts Neurotensin –
F05 Ntsr1 Neurotensin receptor 1 Ntsr
F06 Oprk1 Opioid receptor, kappa 1 –
F07 Oprm1 Opioid receptor, mu 1 MORA, Oprm, Oprrm1
F08 Sigmar1 Sigma non-opioid intracellular receptor 1 Oprs1
F09 Pomc Proopiomelanocortin Pomc1, Pomc2
F10 Ppara Peroxisome proliferator activated receptor alpha PPAR
F11 Pparg Peroxisome proliferator-activated receptor gamma –
F12 Ppargc1a Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha Ppargc1
G01 Ptpn1 Protein tyrosine phosphatase, non-receptor type 1 MGC93562, Ptp
G02 Pyy Peptide YY (mapped) GHYY, RATGHYY, Yy, peptide-YY
G03 Ramp3 Receptor (G protein-coupled) activity modifying protein 3 –
G04 Sort1 Sortilin 1 Nt3, Nts3
G05 Sst Somatostatin SS-14, SS-28, Smst
G06 Sstr1 Somatostatin receptor 1 Gpcrrna
G07 Thrb Thyroid hormone receptor beta C-erba-beta, ERBA2, Nr1a2, RATT3REC, T3rec, TRbeta
G08 Tnf Tumor necrosis factor (TNF superfamily, member 2) MGC124630, RATTNF, TNF-alpha, Tnfa
G09 Trh Thyrotropin releasing hormone THR, TRH01
G10 Trhr Thyrotropin releasing hormone receptor –
G11 Ucn Urocortin –
G12 Ucp1 Uncoupling protein 1 (mitochondrial, proton carrier) MGC108736, Ucp, Ucpa, Uncp
H01 Rplp1 Ribosomal protein, large, P1 MGC72935
H02 Hprt1 Hypoxanthine phosphoribosyltransferase 1 Hgprtase, Hprt, MGC112554
H03 Rpl13a Ribosomal protein L13A –
H04 Ldha Lactate dehydrogenase A Ldh1
H05 Actb Actin, beta Actx
H06 RGDC Rat Genomic DNA Contamination RGDC
H07 RTC Reverse Transcription Control RTC
H08 RTC Reverse Transcription Control RTC
H09 RTC Reverse Transcription Control RTC
H10 PPC Positive PCR Control PPC
H11 PPC Positive PCR Control PPC
H12 PPC Positive PCR Control PPC
doi:10.1371/journal.pone.0038332.t001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38332Figure 1. Rat obesity PCR Array. (A) Functional gene grouping in 3 colors: orexigenic genes in red, anorectic genes in yellow, and genes involved
in energy expenditure in green. (B) The CT value of quality control used rat genomic DNA.
doi:10.1371/journal.pone.0038332.g001
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Bradford protein assay (Bio-Rad Life Science, Hercules, CA). A
total of 90 mg of protein from each of the pooled samples in the
control, HF, and HF+GTP groups were separated by 12% SDS-
polyacrylamide gel electrophoresis and then transferred to
polyvinylidene fluoride (PVDF) membranes. The immobilized
proteins were then incubated overnight at 4uC in blocking buffer
containing 3% nonfat dry milk in 16 phosphate buffered saline
(PBS) and 0.1% Tween 20 (16 PBST). After blocking, the
membranes were probed with the primary antibody (anti-SOD1
or anti-COMT, Santa Cruz Biotechnology, Santa Cruz, CA) for
1 h. Antibody binding was detected with donkey anti-rabbit IgG-
HRP for 1 h at room temperature. After a brief incubation with
enhanced chemiluminescence, the signals on membranes were
exposed to X-ray films. Relative densitometric digital analysis of
protein bands were determined using Quantity One software (Bio-
Rad) and normalized by the intensity of the housekeeping gene (a-
Tubulin, Abcam, Cambridge, MA) for each sample.
Statistical Analyses
Data are expressed as mean 6 standard error (SE), unless
stated. Data of body weight were analyzed by one-way analysis of
variance (ANOVA) with repeated measures followed by Fisher
protected least significant difference (Fisher’s LSD) post-hoc tests
to evaluate the effects of time and treatment. Data from RT-PCR
were quantified by the ABI sequence detection software and
normalized by 5 housekeeping genes (endogenous control). DCT
was defined as the value of subtracting the CT value of endogenous
control from the CT value of the target messenger RNA (mRNA).
The fold change among groups could be obtained by DDCT.
P value less than 0.05 based on t-test was used as the criteria to
determine the differentially expressed genes. Data of serum
biomarkers were analyzed by one-way ANOVA followed by
Fisher’s LSD post-hoc tests to evaluate the treatment effects. For
the protein expression levels among the control, HF, and
HF+GTP groups, one-way ANOVA and Tukey’s post hoc tests
were used to compare densitometric intensity of individual samples
between groups. All analyses were performed using SPSS software
(SPSS, Inc., Chicago, IL, USA) and differences with P,0.05 were
considered statistically significant.
Results
Food Intake and Body Weight
Throughout the study, the average food consumption was
similar among the treatment groups (13.961.6, 12.860.6, and
12.161.1 g/day for the control, HF, and HF+GTP groups,
respectively). The caloric intakes were 53.566.2, 60.562.8, and
57.265.2 kcal/day for the control, HF, and HF+GTP groups,
respectively. No difference in initial body weight was seen among
all treatment groups (Figure 2). The HF-treated group had
significantly greater body weight as compared to the control group
at 4 months. At the end of study, supplementation of GTP in
drinking water (the HF+GTP group) significantly prevented
weight gain compared to the high fat only diet (the HF group)
(P,0.05, Figure 2) with an order of body weight: the HF group.
the HF+GTP group = the control group.
Gene Expression Alterations
The triplicate samples from each group produced reproducible
results. A total of 35 genes (as measured by CT value) were
assigned as undetectable in all groups, leaving 49 genes detected
(Tables S1, S2, and S3 and Figure 3A). Relative to the control
group, the HF group significantly decreased expression of 11 genes
[adenylate cyclase activating polypeptide 1 (pituitary) receptor 1
(Adcyap1r1), adrenergic beta-1-receptor (Adrb1), agouti related
protein homolog (Agrp), apolipoprotein A-IV (Apoa4), ciliary
neurotrophic factor receptor (Cntfr), growth hormone receptor
(Ghr), ghrelin/obestatin prepropeptide (Ghrl), insulin 1 (Ins1),
leptin receptor (Lepr), nuclear receptor subfamily 3 group C
member 1 (Nr3c1), and sortilin 1 (Sort1)] and increased that of
interleukin 1 beta (IL-1b)( P ,0.05, Figure 3B). Supplementation
of GTP to drinking water (the HF+GTP group) significantly
reverted the gene expression levels of IL-1b and Ins1 compared to
those of the non-supplemented group (the HF group) (P,0.05,
Figure 3C). In addition, the gene expression of interleukin 6
receptor alpha (IL-6ra) was significantly increased in the HF+GTP
group compared to the HF group (P,0.05, Figure 3C). Finally,
Nr3c1 was the only gene showing significantly down-regulation in
the HF+GTP group as compared to the control group (P,0.05,
Figure 3D).
Blood Analysis
The serum levels of IL-1b and IL-6 in the control, HF, and
HF+GTP groups are shown in Figure 4. In comparison to the
control group or the HF+GTP group, the HF group had the
highest serum IL-1b and IL-6 concentrations while the HF+GTP
group had the lowest serum IL-1b and IL-6 concentrations.
Compared to the HF group, 4-month GTP supplementation to
the HF diet (the HF+GTP group) caused a significant decrease of
serum proinflammatory cytokines including IL-1b and IL-6
(P,0.05, Figure 4).
Western Blot Analyses of SOD1 and COMT Protein
Expression
The relative protein expression levels of SOD1 and COMT are
shown in Figure 5. SOD1 expression level was significantly
decreased in the HF group as compared to the control group
(P,0.01, Figure 5A). On the other hand, SOD1 expression level
was significantly increased in the HF+GTP group as compared to
either HF or control groups (P,0.01, Figure 5A). The expression
Figure 2. Body weight in female rats supplemented with green
tea polyphenols (GTP) in drinking water for 4 months. Body
weight (g) of the control, HF, and HF+GTP treated rats at 0–8 months.
Values are mean (n=10–12) with their standard error (SE) represented
by vertical bars. * P,0.05 between the control and HF groups; #
P,0.05 between the HF and HF+GTP groups;ˆ P,0.01 between the
control and HF+GTP groups.
doi:10.1371/journal.pone.0038332.g002
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compared to the control group (P,0.05, Figure 5B).
Discussion
Numerous studies in genetic, metabolic, hormonal, behavioral,
social, and cultural aspects have been conducted to increase our
understanding of the cause and treatment of obesity
[3,4,24,25,26]. The physiological and molecular changes observed
in this high-fat-induced obese rat model provide a useful insight
into the development of obesity in humans. In the study, we also
measured % fat mass in the animals using the ImpediVET
TM
Bioimpedance Spectroscopy device (ImpediMed Limited, Bris-
bane, Australia) at the beginning and the end of study. There was
no difference in % fat mass among the groups at the baseline
(21.5160.97, 21.1661.10, and 23.6160.83 for the control, HF,
and HF+GTP groups, respectively). At the end of study, the order
of % fat mass was the HF group (31.3660.82) . the HF+GTP
group (27.7860.79) = the control group (25.7860.76). Consistent
with other reports of obesity models [27,28], obese rats by a HF
diet resulting in a significant increase in % fat mass indicates the
difference in body weight was due to mainly the increased fat
mass.
In the present study, we have shown that a number of genes
involved in obesity changed in HF-treated rats, which further
demonstrated the usefulness of this rat model. In addition, our
results showed the reduced and controlled weight due to the anti-
obesity activity of GTP supplementation. This beneficial effect
could be a result of GTP-induced alteration of obesity related
genes, anti-inflammation activity, anti-oxidative stress capacity, as
well as estrogen-like actions which in turn regulate appetite,
metabolism, or absorption of calories.
A total of 12 obesity-related genes showed significant changes in
the HF-treated obese rats as compared to those of the control.
Among these, Adcyap1r1, Adrb1, Agrp, Apoa4, Cntfr, Ghr, Ghrl,
Ins1, Lepr, Nr3c1, and Sort1 decreased significantly while IL-1b
increased significantly in the HF group in comparison with those
in the control group. There is considerable evidence that these
genes play three critical roles in the pathogenesis of obesity,
including orexigenic function, anorectic function, and energy
expenditure.
Agrp, Ghrl, and Nr3c1 are classified as orexigenic genes. Agrp is
one of the most potent and long-lasting of appetite stimulators
[29,30]. The appetite stimulating effects of Agrp are inhibited by
the hormone leptin (higher in the HF group than the control
Figure 3. The changes of obesity-related genes among the control, HF, and HF+GTP groups. (A) Representative PCR array gene tables of
undetected genes and detected genes. (B) The heat map demonstrating fold regulation expression data between the HF group and the control
group. Genes with significant differences between two groups are shown in the histogram. (C) The heat map demonstrating fold regulation
expression data between the HF+GTP group and the HF group. Genes with significant differences between two groups are shown in the histogram.
(D) The heat map demonstrating fold regulation expression data between the HF+GTP group and the control group. Genes with significant
differences between two groups are shown in the histogram.
doi:10.1371/journal.pone.0038332.g003
GTP’s Effects on Obesity
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(Ghrl, lower in the HF group than the control group). Ghrelin
(Ghrl) is the endogenous ligand for the growth hormone
secretagogue receptor (GHSR) for maintaining growth hormone
(GH) release and energy homeostasis [31]. Previous studies have
demonstrated the decreased level of circulating ghrelin in humans
with obesity [32,33]. Similarly, Nr3c1, the glucocorticoid receptor
gene, has been reported to be involved in hyperinsulinaemia, fat
deposition, and inflammatory responses associated with obesity
[34]. Nr3c1 mRNA levels have also been reported to be
significantly decreased in obesity [35,36].
Apoa4, Cntf, Ghr, IL-1b, Ins1, Lepr, and Sort are anorectic
genes. Apolipoprotein (Apoa4 or Apo A-IV), activated through a
dietary fat-elicited satiety signal [37,38], is involved in various
activities, such as antioxidant activity, cholesterol transporter
activity, lipid binding, phosphatidylcholine binding [39,40,41].
Therefore, the decreased gene expression level of Apoa4 in the HF
group could contribute to diet-induced obesity. Cntfr can mimic
the biological actions of leptin while overcoming ‘‘leptin
resistance’’ [42]. Ghr has profound effects on adipogenesis,
lipogenesis and lipolysis by inducing alterations in the central
nervous system [43,44]. Studies have suggested that decreased Ghr
availability could result in obesity [45,46]. Insulin, which plays
important roles in regulating carbohydrate and fat metabolism in
the body, is commonly deficient or resistant in obese patients [47].
The decreased gene expression level of Ins1 in the HF group
further supports this rat obese model. Leptin is one of the most
important adipose derived hormones, which secretes into the
bloodstream and is transported to the brain, where it stimulates or
inhibits release of several neurotransmitters [48,49,50]. In line
with our findings, lepr and subsequent signaling events have been
reported to be down-regulated in the liver of dietary-induced
obese rats [51]. Finally, sortilin exhibits the strongest association
with serum lipoproteins by degrading nascent VLDL particles
[52,53].
Adcyap1r1 and Adrb1 are the two genes that relate to energy
expenditure. Adcyap1r1 can influence the control of energy
homeostasis and has remarkable anti-inflammation action [54,55].
Adrb1 induces lipolysis in adipose tissue [56]. In all, the altered
expression levels of 12 obesity genes in the HF group, as compared
to the control group, suggest a qualified obese model, which could
result in reverted obesity via regulating the expression of obesity-
related genes. The obesity model used in our study may more
closely simulate the onset of obesity in humans, rather than the
genetic alteration or mutation induced obesity models.
The findings that GTP supplementation into the drinking water
reversed the expression levels of 11/12 genes (except Nr3c1) in
obese rats corroborates the anti-obesity role of GTP. For instance,
our findings of increased Adcyap1r1 and Adrb1 after GTP
treatment are in agreement with studies, demonstrating that green
tea increases energy expenditure [57,58,59], and has proved
effective in reducing body fat partially mediated via Adrb1
activation [60].
Chronic systemic inflammation directly contributes to the
development of obesity [5,54–57]. For instance, overweight and
obese women generally have elevated serum levels of inflammation
cytokines, such as IL-6 and TNF-a [61,62,63]. Therefore,
suppressing chronic inflammation may be a good strategy to
prevent and/or treat obesity. The observations that the HF group
increased IL-1b gene expression agrees with Matsuki et al. that IL-
1b is harmful for the energy homeostasis of the body through its
role in lipid metabolism by regulating insulin levels [64]. GTP
supplementation suppressed the chronic inflammation due to a
high-fat diet in the present study, as shown by decreased IL-1b
gene expression and circulating IL-1b and IL-6 levels, as well as
increased IL-6ra and Inl1 gene expression. However, although
Figure 4. Proinflammatory cytokines changes among the control, HF, and HF+GTP groups. Results are expressed as mean6SE. # P,0.05
between the HF and HF+GTP groups.
doi:10.1371/journal.pone.0038332.g004
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of the HF group were observed as compared to those of the
control, these differences did not reach statistical significances.
This might due to the large variations within the groups.
Therefore, future studies using a larger sample size are warranted.
One of the other most widely recognized characteristics of
obesity is the increased oxidative stress [65]. GTP has shown its
anti-oxidant activities, stemming from its ability to scavenge
reactive oxygen species [66]. In the present study, GTP
supplementation increased SOD1 expression (an indicator of
antioxidant capacity) in obese rats. Our results are consistent with
the anti-obesity role of GTP by increasing antioxidant capacity
and/or decreasing oxidative stress damage, which is commonly
observed in obesity [20,24,67,68,69].
Although there was no statistically significant difference in
COMT protein expression between the HF+GTP group and the
HF group due to the large variation, this restoration of COMT
made no statistical significance between HF+GTP and control
groups. COMT activity is important in fat regulation, since
preadipocyte proliferation and differentiation can be inhibited by
2-methoxyestradiol, the synthesis of which is catalyzed by COMT
[70]. Weight loss results in a reduction in circulating estrogens
[71,72]. Therefore, the restoration of COMT expression observed
after GTP treatment would inhibit the activation of estrogen by
catalyzing the methylation of catechol estrogens to less active
methoxy estrogens (e.g., 2-methoxyestradiol). Moreover, COMT
has been shown to be involved in reward-motivated behaviors
such as development of diet-induced obesity through metabolizing
dopamine [73]. Taken together, the GTP-induced weight loss may
possibly and partially result from increased COMT through its
regulation of estrogen and appetite.
Among all the 84 genes related to obesity, a total of 35 genes
were not detected in all 3 groups of our rat liver samples. There
might be reasons such as genes are not (or very weakly) expressed
in the liver tissues, for example Brs3, which is normally expressed
in the brain, kidney, and testis. Calcr is normally expressed in the
brain and kidney. Cartpt can be detected in the brain, spinal cord,
prostate, and testis but not in the liver [74]; and the detection
sensitivity of gene array is limited. On the other hand, due to the
mixture of cell types in tissue samples, the magnitude of expression
changes of some genes might not be detected.
Studies including ours have demonstrated the effects of green
tea on weight loss. Possible mechanisms behind this may result
from the observation of lower serum and LDL cholesterol,
increased HDL cholesterol, and lower serum glucose [75,76,77];
the increase in fat mobilization and oxidation [15,16,78,79]; the
increase in energy expenditure [80] and appetite suppression
[81,82]; as well as the reduction in the absorption of nutrients [83]
as a result of GTP treatment. However, there are still debates of
the overall effects of GTP that show some inconsistent results
[84,85,86,87]. For instance, several studies have failed to show
differences in assessed subjective appetite or energy intake after
green tea consumption, despite favorable outcomes for body
weight and body fat [6,12,88]. These might partially due to the
variation and/or the sensibility of detecting small changes in
dietary intake, which are hard to be accurately measured with
available techniques. As an outcome, this minor imbalance
between energy intake and energy expenditure over years may
lead to severe obesity. In fact, in lines with these findings, the
correlation between the changes of orexigenic genes and the
behavior of appetite was not observed in our current study.
Collectively, this could lead to the difficulty in assessing the
etiology of obesity as well as the protective effects of GTP
supplement. Nevertheless, our study firstly demonstrated the
Figure 5. Western blot analyses of protein expression in the
control, HF, and HF+GTP groups. (A) Effects of HF and HF+GTP
treatment on the protein expression of SOD1. (B) Effects of HF and
HF+GTP treatment on the protein expression of COMT. Blots were also
probed for a-tubulin to confirm equal protein loading. The relative
protein intensities of SOD1 and COMT were compared with the intensity
of a-tubulin. The intensity of each band was quantified using Quantity
One software. Data are means6SE, n=3. The experiments were
conducted in triplicate. * P,0.05 between the control and HF groups;
** P,0.01 between the control and HF groups; ## P,0.01 between HF
and HF+GTP;ˆ ˆ P,0.01 between the control and HF+GTP groups.
doi:10.1371/journal.pone.0038332.g005
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while GTP supplement could reverse the effects of these genes.
The study strategy conducted in the present study could provide
an additional concept in assessing not only the etiologic
mechanisms of obesity but the beneficial effects of GTP. However,
this study is limited in lacking a control+GTP group which would
provide additional evidences to demonstrate the beneficial effects
of GTP supplement. In addition, the study using male mice could
be helpful in expanding the findings of the present study to better
understand the protective effects of GTP supplement in obesity.
In summary, our data demonstrated that GTP supplementation
has potent effects on body weight in obese middle-aged female rats
through regulating obesity-related genes, anti-inflammation activ-
ity, anti-oxidative stress capacity, as well as estrogen-associated
actions. We believe that our study presents a critical first step
towards evaluating the effects of green tea consumption in obese
middle-aged women. Translational research based on findings
from animal observations to investigate possible therapeutic
efficacy of GTP on obese women will be worthy in a future study.
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